| |
| |
| |
Centre for Policy on Ageing | |
 | |
|
| Assessing the cost-effectiveness of the rivastigmine transdermal patch for Alzheimer's disease in the UK using MMSE- and ADL-based models | | Author(s) | Balazs Nagy, Alan Brennan, Agnes Brandtmuller |
| Journal title | International Journal of Geriatric Psychiatry, vol 26, no 5, May 2011 |
| Pages | pp 483-494 |
| Source | http://www.interscience.wiley.com/journal/gps |
| Keywords | Dementia ; Drugs ; Cost effectiveness ; Clinical surveys. |
| Annotation | The study aimed to assess the long-term cost-effectiveness of rivastigmine patch in Alzheimer's disease (AD) management in the UK, using cognitive and functional models based on clinical trial efficacy data. Incremental costs and Quality Adjusted Life Years (QALYs) associated with rivastigmine patch and capsule treatment versus best supportive care (BSC) were calculated using two economic models, one based solely on Mini-Mental State Examination (MMSE) scores, and one also incorporating activities of daily living (ADL) scores. The clinical pathway was populated with data from a clinical trial of rivastigmine patch (9.5 mg/24 h) and capsules (12 mg/day) versus placebo. Costs were based on the UK health and social care costs and basic UK National Health Service (NHS) prices. Disease progression was modelled beyond the trial period over five years using published equations to predict natural decline in AD patients. Base case costing variables included drugs, clinical monitoring, and institutionalisation. The MMSE model estimated incremental costs per QALY of £10,579 for rivastigmine patch and £15,154 for capsule versus BSC. The MMSE-ADL model estimated incremental costs per QALY of £9,114 for rivastigmine patch and £13,758 for capsules. Both the MMSE and MMSE-ADL models suggest that rivastigmine patch and capsules are cost-effective treatments. (JL). |
| Accession Number | CPA-110822002 A |
| Classmark | EA: LLD: WEC: 3G |
Data © Centre for Policy on Ageing |
|
| ...from the Ageinfo database published by Centre for Policy on Ageing. |
| |
|
|